Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Forodesine in Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma
NCT00419081Phase 2Terminated
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Jul 2006
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of forodesine in Precursor T-cell acute lymphoblastic leukemia (T-ALL), Precursor T lymphoblastic lymphoma (T-LBL), sponsored by BioCryst Pharmaceuticals, Inc.. Started Jul 2006; status: terminated.
02
Drugs
forodesine
03
Conditions
Precursor T-cell acute lymphoblastic leukemia (T-ALL)Precursor T lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT00419081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00419081.